Skip to content


Harvoni (ledipasvir) is a small molecule pharmaceutical. Ledipasvir was first approved as Harvoni on 2014-10-10. It is used to treat chronic hepatitis c and hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c. Harvoni's patents are valid until 2034-01-30 (FDA).
Trade Name Harvoni
Common Name Ledipasvir
Indication chronic hepatitis c, hepatitis c
Drug Class Antivirals: NS5A inhibitors
Get full access now